Related Experiment Videos
Cardiotoxicity of 5-flourouracil: two case reports
1Marmara Universitesi Hastanesi, Kulak Burun Bogaz ABD, Tophanelioglu cad. no: 13-15, 81190 Altunizade, Istanbul, Turkey. selcukinanli@hotmail.com
Auris, Nasus, Larynx
|March 10, 2001
Summary
Cardiotoxicity from 5-fluorouracil (5-FU) chemotherapy is a serious risk, often linked to coronary artery vasospasm. Careful patient selection and monitoring during 5-FU infusion are crucial to manage this rare but severe side effect.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- 5-fluorouracil (5-FU) is a widely used chemotherapy agent.
- Cardiotoxicity is an increasingly recognized, albeit rare, side effect of 5-FU treatment.
- The incidence of 5-FU cardiotoxicity is rising due to its frequent use in various chemotherapy regimens.
Observation:
- 5-FU cardiotoxicity manifests as ischemic symptoms and signs.
- These adverse cardiac events typically occur during the later stages of drug administration.
- Coronary artery vasospasm and the toxic metabolite flouroacetate are proposed as primary mechanisms.
Findings:
- The exact mechanism of 5-FU-induced cardiotoxicity is not fully elucidated, with several theories proposed.
- Coronary artery vasospasm and flouroacetate, a toxic metabolite, are commonly implicated.
- Ischemic cardiac events are observed during the late phase of 5-FU administration.
Implications:
- Close monitoring of patients during 5-FU infusion is mandatory, particularly those with pre-existing coronary artery disease.
- There is currently no single effective treatment or prophylactic measure for 5-FU cardiotoxicity.
- Careful patient selection for 5-FU therapy and prompt discontinuation upon symptom onset are essential management strategies.